Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sphinxolide B is a naturally occurring marine macrolide compound classified as a diterpene lactone. It was originally isolated from the marine sponge Reidispongia coerulea and is notable for its complex structure and potent cytotoxic activity in preclinical models[2][8]. Sphinxolide B acts as a microfilament (actin) destabilizing agent and has been studied for its potential anticancer properties due to its ability to disrupt actin dynamics in cells[7][8]. Its mechanism involves binding to actin filaments and interfering with their stability—an action that can induce apoptosis or inhibit proliferation in cancer cells[7]. There are no approved therapeutic indications or marketed formulations of sphinxolide B; it remains an experimental compound primarily used in research settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sphinxolide B.